Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Esther Peluso
Observed names:
E Peluso,
Esther M Peluso,
Esther M. Peluso
Institutions:
California Institute of Technology,
University of California, Los Angeles
Observed institutions:
California Institute of Technology,
La Jolla Institute for Immunology,
University of California, Los Angeles
ORCID:
0000-0002-0252-6327
Observed ORCID:
0000-0002-0252-6327
OpenAlex ID:
A5025267202
Patrolling monocytes control tumor metastasis to the lung
2015
·
Richard N. Hanna
, Caglar Cekic
, et al.
·
Science
·
537
Human Protein- l -isoaspartate O-Methyltransferase Domain-Containing Protein 1 (PCMTD1) Associates with Cullin-RING Ligase Proteins
2022
·
Rebeccah A. Warmack
, Eric Z. Pang
, et al.
·
Biochemistry
·
13
Polyfunctional T follicular helper cells drive checkpoint-inhibitor diabetes and are targeted by JAK inhibitor therapy
2025
·
Nicole L. Huang
, Jessica G. Ortega
, et al.
·
JCI Insight
·
8
PDF
Metastatic squamous cell carcinoma arising from mature teratoma of the ovary: Description of multi-modality treatment including incorporation of adjuvant immunotherapy and maintenance PARP inhibitor therapy
2024
·
Esther Peluso
, Wesleigh Fowler Edwards
, et al.
·
Gynecologic Oncology Reports
·
8
Sex Matters: Hormonal and Chromosomal Determinants of Autoimmunity and Anti‐Cancer Immunity Across the Lifespan
2026
·
Christian G. Bustillos
, Esther M. Peluso
, et al.
·
Immunological Reviews
·
6
PDF
Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer
2025
·
Alexis LeVee
, Esther Peluso
, et al.
·
The Oncologist
·
2
PDF
UTX coordinates TCF1 and STAT3 to control progenitor CD8+ T cell fate in autoimmune diabetes
2025
·
Ho-Chung Chen
, Madison F. Bang
, et al.
·
Journal of Clinical Investigation
·
1
PDF
Medullary Thyroid Carcinoma and Clinical Outcomes in Heterozygous Carriers of the RET K666N Germline Pathogenic Variant
2025
·
Allison T Yip
, Teresa H Kim
, et al.
·
JCEM Case Reports
·
1
PDF
1176 Anti-RANKL bone resorptive therapy increases immune related adverse events (irAEs) during checkpoint inhibitor therapy
2024
·
Esther Peluso
, Jessica Ortega
, et al.
·
Journal for ImmunoTherapy of Cancer
·
1
PDF
8439 Targeting Interferon Gamma-Mediated CXCL16-CXCR6 Chemokine-Receptor Interactions As A Strategy To Prevent Immune Checkpoint Inhibitor Autoimmune Diabetes
2024
·
S Wang
, N Huang
, et al.
·
Journal of the Endocrine Society
·
1
Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1
2026
·
Alexandra Lim
, Esther M Peluso
, et al.
·
JCEM Case Reports
Abstract B040: Androgen signaling attenuates granzyme B production in CD8+ T cells in ICI-Colitis
2026
·
Esther M. Peluso
, Amber Lu
, et al.
·
Cancer Immunology Research
Abstract PS5-04: Anti-RANKL bone resorptive therapy increases immune-related adverse events (irAE) in breast cancer patients (pts) treated with pembrolizumab
2025
·
Alexis LeVee
, Esther Peluso
, et al.
·
Clinical Cancer Research
Show more works
View as search
Works count:
13
Citation count:
578
H-index:
5
I10-index:
2
Year
Topic
Type